Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-PSMA/anti-CD28 bispecific antibody JNJ-87189401

A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-PSMA/anti-CD28 bispecific antibody JNJ-87189401 binds to both CD28 expressed on cytotoxic T lymphocytes (CTLs) and PSMA expressed on tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-PSMA/CD28 bispecific antibody JNJ-87189401
PSMA x CD28 bispecific antibody JNJ-87189401
PSMA-CD28 bispecific antibody JNJ-87189401
Code name:JNJ 87189401
JNJ-87189401
JNJ87189401
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search